Medicsight and Korea's Infinitt team up:
This article was originally published in Clinica
Executive Summary
UK computer-aided detection (CAD) firm Medicsight and Korean imaging and picture archiving and communication systems (PACS) specialist Infinitt are set to combine their technologies in a global marketing deal. Medicsight's ColonCAD software for the detection of colorectal cancer will be integrated into Infinitt's PACS and 3D Rapidia virtual colonoscopy workstations, and distributed through Infinitt's global sales network. According to London-based Medicsight, Infinitt is the PACS market leader in South Korea, and has joint ventures in Japan, China, Taiwan and the US. Financial details of the deal were not disclosed.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.